Baidu
map

药械

订阅

MedSci主页 / 所有栏目 / 药械

Watson公司仿制药Budesonide获FDA批准上市

2012-08-06 任冰鉴 生物谷

Watson仿制药BudesonideFDA
关注

 Watson 制药公司下属的Watson实验室简化药物（ANDA）Budesonide悬浮吸入剂获FDA批准。推荐的剂量为0.25mg/2ml和0.5mg/2ml。 Budesonide悬浮吸入剂是阿斯利康旗下药物普米令克舒（Pulmicort RESPULES）的仿制药。是一种用于缓解1-8岁幼儿哮喘症状的维持药物。 Watson制药希望在2012年将这一药物投入市场。阿斯利康目

 Watson 制药公司下属的Watson实验室简化药物（ANDA）Budesonide悬浮吸入剂获FDA批准。推荐的剂量为0.25mg/2ml和0.5mg/2ml。

Budesonide悬浮吸入剂是阿斯利康旗下药物普米令克舒（Pulmicort RESPULES）的仿制药。是一种用于缓解1-8岁幼儿哮喘症状的维持药物。

Watson制药希望在2012年将这一药物投入市场。阿斯利康目前正针对这一药物提起诉讼，Waston希望在可能的禁令出现以前做出预先的行动。

根据IMS的数据，截止至2012年5月31日，在持续12个月的销售中，普米令克舒在美国的销售额达到了11亿美元。

 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=49312, encodeId=15d7493123f, content=有内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:21:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068153, encodeId=25732068153cc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Nov 24 03:17:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839174, encodeId=57fd18391e4e7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Mar 17 20:17:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991378, encodeId=703d19913e807, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 04 09:17:00 CST 2013, time=2013-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261298, encodeId=02ee126129860, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493264, encodeId=d60d1493264db, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558484, encodeId=b0eb1558484e8, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564493, encodeId=1f4d15644932c, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    有内容

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=49312, encodeId=15d7493123f, content=有内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:21:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068153, encodeId=25732068153cc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Nov 24 03:17:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839174, encodeId=57fd18391e4e7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Mar 17 20:17:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991378, encodeId=703d19913e807, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 04 09:17:00 CST 2013, time=2013-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261298, encodeId=02ee126129860, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493264, encodeId=d60d1493264db, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558484, encodeId=b0eb1558484e8, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564493, encodeId=1f4d15644932c, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
    2012-11-24 12499e01m47暂无昵称

    #ATS#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=49312, encodeId=15d7493123f, content=有内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:21:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068153, encodeId=25732068153cc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Nov 24 03:17:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839174, encodeId=57fd18391e4e7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Mar 17 20:17:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991378, encodeId=703d19913e807, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 04 09:17:00 CST 2013, time=2013-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261298, encodeId=02ee126129860, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493264, encodeId=d60d1493264db, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558484, encodeId=b0eb1558484e8, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564493, encodeId=1f4d15644932c, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
    2013-03-17 bugit

    #FDA批准#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=49312, encodeId=15d7493123f, content=有内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:21:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068153, encodeId=25732068153cc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Nov 24 03:17:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839174, encodeId=57fd18391e4e7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Mar 17 20:17:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991378, encodeId=703d19913e807, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 04 09:17:00 CST 2013, time=2013-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261298, encodeId=02ee126129860, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493264, encodeId=d60d1493264db, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558484, encodeId=b0eb1558484e8, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564493, encodeId=1f4d15644932c, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
    2013-06-04 caobinglei8079

    #Watson#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=49312, encodeId=15d7493123f, content=有内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:21:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068153, encodeId=25732068153cc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Nov 24 03:17:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839174, encodeId=57fd18391e4e7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Mar 17 20:17:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991378, encodeId=703d19913e807, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 04 09:17:00 CST 2013, time=2013-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261298, encodeId=02ee126129860, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493264, encodeId=d60d1493264db, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558484, encodeId=b0eb1558484e8, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564493, encodeId=1f4d15644932c, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
    2012-08-08 drwjr

    #仿制药#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=49312, encodeId=15d7493123f, content=有内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:21:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068153, encodeId=25732068153cc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Nov 24 03:17:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839174, encodeId=57fd18391e4e7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Mar 17 20:17:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991378, encodeId=703d19913e807, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 04 09:17:00 CST 2013, time=2013-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261298, encodeId=02ee126129860, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493264, encodeId=d60d1493264db, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558484, encodeId=b0eb1558484e8, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564493, encodeId=1f4d15644932c, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
    2012-08-08 hongbochen

    #ESO#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=49312, encodeId=15d7493123f, content=有内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:21:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068153, encodeId=25732068153cc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Nov 24 03:17:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839174, encodeId=57fd18391e4e7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Mar 17 20:17:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991378, encodeId=703d19913e807, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 04 09:17:00 CST 2013, time=2013-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261298, encodeId=02ee126129860, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493264, encodeId=d60d1493264db, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558484, encodeId=b0eb1558484e8, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564493, encodeId=1f4d15644932c, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
    2012-08-08 fusion

    #DES#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=49312, encodeId=15d7493123f, content=有内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:21:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068153, encodeId=25732068153cc, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Nov 24 03:17:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839174, encodeId=57fd18391e4e7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Mar 17 20:17:00 CST 2013, time=2013-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991378, encodeId=703d19913e807, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 04 09:17:00 CST 2013, time=2013-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261298, encodeId=02ee126129860, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493264, encodeId=d60d1493264db, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558484, encodeId=b0eb1558484e8, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564493, encodeId=1f4d15644932c, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Wed Aug 08 01:17:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
    2012-08-08 fusion

    #DES#

    0

Baidu
map
Baidu
map
Baidu
map